POKO Poprad s.r.o.

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Melanoma4 trials
• Colorectal cancer3 trials
• Childhood cancers1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial
• Sarcoma1 trial

Phase

• Phase 36 trials
• Phase 24 trials

Status

• Completed6 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Pfizer5 trials
• Bayer1 trial
• F. Hoffmann-La Roche AG1 trial
• Hoffmann-La Roche1 trial
• NGM Biopharmaceuticals, Inc1 trial
• and 1 more

Running trials

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Recruiting

  An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

  NCT07033026· Phase 2· NGM Biopharmaceuticals, Inc· Source

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Bayer· Source

• Recruiting

  Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Phase 2· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Completed

  Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed During or After Prior Treatment with Anti−PD-1 Therapy

  2023-509471-17-00· Phase 2· Pfizer Inc.· Source

• Completed

  A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

  NCT05419388· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

  NCT04657991· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Pfizer· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source